Clinical Trial Update: Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating recombinant interleukin-21 in combination with sorafenib for metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interleukin-21 (recombinant) (Interleukin-21)
• Sorafenib (Sorafenib)

Snippet

Sponsor: ZymoGenetics | Conditions: Carcinoma, Renal Cell | Phase 1, Phase 2 | Status: COMPLETED